retatrutide phase 2 nejm 2023 obesity trial results triple agonist for diabetes type hormone receptor metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide is gaining attention in – retatrutide clinical trial outcomes The – Another Promising Medication (Retatrutide) for

Lowering drug prices in the U.S

For someone with lupus or RA, thats a problem on top of a problem

The thesis most analysts are running is a structural growth compounder: a business with 80% of its addressable sleep apnea market still undiagnosed, a recurring-revenue mask and accessories segment that now generates double-digit annual growth, and a margin profile expanding toward 37% EBIT margins by fiscal 2027 estimates

By helping people lose weight and improve insulin resistance, these medications can help restore hormonal balance and make ovulation more regular

Current Opinion in Endocrinology and Diabetes, 12:56-62, 2005